Table 1.
Clinical trials of EpCAM, HER family, CEA- and PSMA-related BsAbs in solid tumors
| BsAb | Targets | Format | Function | Diseases | Phase | Stage | Identifier |
|---|---|---|---|---|---|---|---|
| Catumaxomab | EpCAM/CD3 | Triomab | Redirect T cells and accessory cells | Ovarian cancer | II | Completed | NCT00189345 |
| Catumaxomab | EpCAM/CD3 | Triomab | Redirect T cells and accessory cells | EpCAM positive tumor, malignant ascites | II/III | Completed | NCT00836654 |
| Catumaxomab | EpCAM/CD3 | Triomab | Redirect T cells and accessory cells | Gastric cancer, adenocarcinoma | II | Completed | NCT00464893 |
| Catumaxomab | EpCAM/CD3 | Triomab | Redirect T cells and accessory cells | Gastric adenocarcinomas | II | Active, not recruiting | NCT01504256 |
| Catumaxomab | EpCAM/CD3 | Triomab | Redirect T cells and accessory cells | Ovarian cancer | II | Completed | NCT01246440 |
| Catumaxomab | EpCAM/CD3 | Triomab | Redirect T cells and accessory cells | Gastric peritoneal carcinomatosis | II | Terminated | NCT01784900 |
| Catumaxomab | EpCAM/CD3 | Triomab | Redirect T cells and accessory cells | Epithelial cancer | I | Terminated | NCT01320020 |
| Catumaxomab | EpCAM/CD3 | Triomab | Redirect T cells and accessory cells | Malignant ascites | III | Completed | NCT00822809 |
| MT110 | EpCAM/CD3 | BiTE | T cell recruitment | EpCAM-positive solid tumors | I | Completed | NCT00635596 |
| Ertumaxomab | HER2/CD3 | Triomab | Redirect T cells and accessory cells | Breast cancer | II | Terminated | NCT00452140 |
| Ertumaxomab | HER2/CD3 | Triomab | Redirect T cells and accessory cells | Breast cancer | II | Terminated | NCT00522457 |
| Ertumaxomab | HER2/CD3 | Triomab | Redirect T cells and accessory cells | Her2 positive advanced solid tumors | I/II | Terminated | NCT01569412 |
| HER2Bi-aATC | HER2/CD3 | T cells armed with BsAbs | Activated T cells | Her2-positive neoplasms | I | Recruiting | NCT02662348 |
| EGFRBi-aATC | EGFR/CD3 | T cells armed with BsAbs | Activated T cells | Advanced solid tumors | I | Terminated | NCT01081808 |
| MDX-447 | EGFR/CD64 | 2(Fab’) | Active monocytes | Brain and central nervous system tumors | I | Completed | NCT00005813 |
| MM-111 | HER2/HER3 | HSA body | Blockade of 2 receptors | HER2 amplified solid tumors | I | Completed | NCT00911898 |
| MM-111 + Herceptin | HER2/HER3 | HSA body | Blockade of 2 receptors | Breast cancer | I | Completed | NCT01097460 |
| MCLA-128 | HER2/HER3 | Full Length IgG1 | Blockade of 2 receptors | Malignant solid tumors | I/II | Recruiting | NCT02912949 |
| MM-141 | HER3/IGF-IR | scFv-IgG | Blockade of 2 receptors | Hepatocellular carcinoma | I | Completed | NCT01733004 |
| MM-141 | HER3/IGF-IR | scFv-IgG | Blockade of 2 receptors | Pancreatic cancer | II | Recruiting | NCT02399137 |
| LY3164530 | EGFR/MET | OrthoFab-IgG | Blockade of 2 receptors | Advanced or metastatic cancer | I | Active, not recruiting | NCT02221882 |
| TargomiRs | EGFR/EDV | Unclear | Delivery of nanoparticles | MPM and NSCLC | I | Recruiting | NCT02369198 |
| EGFR(V)-EDV-Dox | EGFR/EDV | Unclear | Delivery of nanoparticles | Glioblastoma | I | Recruiting | NCT02766699 |
| AMG211 | CEA/CD3 | BiTE | T cell recruitment | Gastrointestinal cancer | I | Recruiting | NCT02760199 |
| AMG211 | CEA/CD3 | BiTE | T cell recruitment | Gastrointestinal cancer | I | Recruiting | NCT02291614 |
| AMG211 | CEA/CD3 | BiTE | T cell recruitment | Gastrointestinal adenocarcinomas | I | Recruiting | NCT01284231 |
| RO6958688 | CEA/CD3 | IgG-based | T cell recruitment | CEA-positive solid tumors | I | Recruiting | NCT02324257 |
| RO6958688+Atezolizumab | CEA/CD3 | IgG-based | T cell recruitment | CEA-positive solid tumors | I | Recruiting | NCT02650713 |
| RO6895882 | CEA/IL2 | ScFv-IgG | The delivery of cytokines | CEA-positive solid tumors | I | Completed | NCT02004106 |
| TF2 | CEA/HSG | Dock and lock | Radioimmunotherapy | Colorectal cancer | I | Completed | NCT00860860 |
| TF2 | CEA/ HSG | Dock and lock | Radioimmunotherapy | Small cell lung cancer | I/II | Completed | NCT01221675 |
| TF2 | CEA/ HSG | Dock and lock | Immuno-PET | Medullary thyroid carcinoma | I/II | Completed | NCT01730638 |
| TF2 | CEA/ HSG | Dock and lock | Immuno-PET | Breast carcinoma expressing CEA | I/II | Ongoing | NCT01730612 |
| TF2 | CEA/ HSG | Dock and lock | Radioimmunotherapy | Colorectal cancer | I | Terminated | NCT01273402 |
| TF2 | CEA/ HSG | Dock and lock | Immuno-PET | Colorectal cancer | II | Completed | NCT02587247 |
| Anti-CEAxanti-DTPA | CEA/di-DTPA-131 | scFv-IgG | Radioimmunotherapy | Medullary thyroid carcinoma | II | Completed | NCT00467506 |
| BAY2010112 | PSMA/CD3 | BiTE | T cell recruitment | CRPC | I | ongoing | NCT01723475 |
| MOR209/ES414 | PSMA/CD3 | ScFv-Fc-scFv | T cell recruitment | mCRPC | I | Recruiting | NCT02262910 |
The details of Table 1 derived from http://clinicaltrials.gov/